share_log

8-K: Poll Results of 2024 Stockholders Meeting

8-K: Poll Results of 2024 Stockholders Meeting

8-K：2024年股东大会会议决议公告
美股SEC公告 ·  05/13 16:34

Moomoo AI 已提取核心信息

Cassava Sciences, Inc., a biopharmaceutical company, held its 2024 Annual Meeting of Stockholders on May 9, 2024. The meeting was conducted virtually with a quorum of approximately 62% of the shares represented. During the meeting, three key proposals were voted upon. The first proposal involved the election of three nominees to the Board of Directors, with Remi Barbier, Sanford R. Robertson, and Patrick J. Scannon, M.D., Ph.D. being elected for a three-year term. The second proposal was the ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024, which passed with a significant majority. The third proposal, a non-binding advisory vote on the 2023 executive compensation for the named executive officers, was also approved. The results of the votes were detailed in the company's definitive proxy statement filed with the U.S. Securities and Exchange Commission on March 26, 2024.
Cassava Sciences, Inc., a biopharmaceutical company, held its 2024 Annual Meeting of Stockholders on May 9, 2024. The meeting was conducted virtually with a quorum of approximately 62% of the shares represented. During the meeting, three key proposals were voted upon. The first proposal involved the election of three nominees to the Board of Directors, with Remi Barbier, Sanford R. Robertson, and Patrick J. Scannon, M.D., Ph.D. being elected for a three-year term. The second proposal was the ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024, which passed with a significant majority. The third proposal, a non-binding advisory vote on the 2023 executive compensation for the named executive officers, was also approved. The results of the votes were detailed in the company's definitive proxy statement filed with the U.S. Securities and Exchange Commission on March 26, 2024.
生物制药公司木薯科学公司于2024年5月9日举行了2024年年度股东大会。会议以虚拟方式进行，法定人数约占所代表股份的62％。会议期间，对三项关键提案进行了表决。第一项提案涉及选举三名董事会候选人，当选的雷米·巴比尔、桑福德·罗伯逊和医学博士帕特里克·斯坎农博士任期三年。第二项提案是批准安永会计师事务所作为截至2024年12月31日的财政年度的独立注册会计师事务所，该提案以绝大多数获得通过。第三项提案，即对指定执行官的2023年高管薪酬进行不具约束力的咨询投票，也获得批准。投票结果详见该公司于2024年3月26日向美国证券交易委员会提交的最终委托书。
生物制药公司木薯科学公司于2024年5月9日举行了2024年年度股东大会。会议以虚拟方式进行，法定人数约占所代表股份的62％。会议期间，对三项关键提案进行了表决。第一项提案涉及选举三名董事会候选人，当选的雷米·巴比尔、桑福德·罗伯逊和医学博士帕特里克·斯坎农博士任期三年。第二项提案是批准安永会计师事务所作为截至2024年12月31日的财政年度的独立注册会计师事务所，该提案以绝大多数获得通过。第三项提案，即对指定执行官的2023年高管薪酬进行不具约束力的咨询投票，也获得批准。投票结果详见该公司于2024年3月26日向美国证券交易委员会提交的最终委托书。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间